Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of iberdomide + daratumumab + dexamethasone versus daratumumab + bortezomib + dexamethasone in relapsed or refractory multiple myeloma
CTR20222913Phase 3Active
- Sponsor
- Celgene Corporation
- Start
- Jan 2023
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of iberdomide in multiple myeloma (MM), sponsored by Celgene Corporation. Started Jan 2023; status: active.
02
Drugs
iberdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20222913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222913.